

5M2026 BUSINESS UPDATES

Imexpharm Corporation

May Performance

Net revenue grew 8% m-o-m, outpacing COGS and driving a 13% m-o-m increase in gross profit. However, y-o-y metrics remained down, with net revenue declining 7% and gross profit dropping 2%.. Intensified marketing and customer servicing initiatives to drive top line recovery led to a 3% y-o-y decline in monthly PBT.

5-Month Performance

Net revenue contracted 11% y-o-y due to headwinds across both OTC and ETC channels. Strict COGS management contained the gross profit decline to 6% y-o-y. Despite top line pressures, 5M PBT and EBITDA grew by 7% and 2% y-o-y, respectively, driven by effective expense management.

TOP **50** CORPORATE SUSTAINABILITY AWARDS



Responsible Consumption & Products



Outstanding Corporate Governance

Major shareholder transition progress



5 May: Livzon Pharmaceutical Group acquired 67.87%



23 June: new BOD to be introduced